ACLY and metabolic dysfunction-associated steatohepatitis: find that combination therapy in mice with the ACLY inhibitor bempedoic acid and the GLP1-R agonist liraglutide leads to greater reductions in NASH and fibrosis than monotherapies and is associated with transcriptional signatures consistent with the resolution of liver fibrosis in clinical populations.